AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35342321 — intervention group
Group type: EXPERIMENTAL
Intervention: E-GPS (Glasgow prognostic score after first-line chemotherapy)
Number of subjects: 138
Study 35342321 — intervention group
Group type: COMPARATOR
Intervention: B-GPS (Glasgow prognostic score at baseline)
Number of subjects: 138
Study 35342457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral infigratinib (dose-escalation, dose-finding, and dose-expansion phases)
Number of subjects: 0
Study 35342457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral infigratinib (specific dose to be confirmed in dose-expansion phase)
Number of subjects: 0
Study 35342457 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline data collection in PROPEL)
Number of subjects: 0
Study 35342822 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 or 2.0 mg) monthly or as-needed (PRN) for 24 months
Number of subjects: 1097
Study 35342978 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg QD
Number of subjects: 0
Study 35342978 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg QD
Number of subjects: 0
Study 35343066 — intervention group
Group type: EXPERIMENTAL
Intervention: WTC RRWV
Number of subjects: 0
Study 35343066 — intervention group
Group type: COMPARATOR
Intervention: Simulated unexposed cohort
Number of subjects: 0
Study 35343066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral dust work exposure
Number of subjects: 0
Study 35343187 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg for six cycles or until disease progression or unacceptable toxicity or withdrawal
Number of subjects: 60
Study 35343187 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg
Number of subjects: 60
Study 35343188 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testing for EGFR mutation analysis
Number of subjects: 245
Study 35343188 — intervention group
Group type: COMPARATOR
Intervention: Tissue sample testing for EGFR mutation analysis
Number of subjects: 245
Study 35343323 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant photon or proton radiotherapy
Number of subjects: 25
Study 35343768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention; specific details not provided
Number of subjects: 0
Study 35343768 — intervention group
Group type: EXPERIMENTAL
Intervention: Metagenomics approach; specific details not provided
Number of subjects: 0
Study 35343910 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAR-004, a smartphone-based investigational digital therapeutic, added to standard treatments for schizophrenia.
Number of subjects: 112
Study 35343910 — intervention group
Group type: COMPARATOR
Intervention: Sham control (nonspecific digital sham control).
Number of subjects: 112
Study 35343910 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAR-004, a smartphone-based investigational digital therapeutic.
Number of subjects: 112
Study 35344040 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0
Study 35344040 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax combined with radiotherapy
Number of subjects: 0
Study 35344040 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 35344040 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax as a monotherapy
Number of subjects: 0
Study 35344082 — intervention group
Group type: EXPERIMENTAL
Intervention: Breech presentation
Number of subjects: 507
Study 35344082 — intervention group
Group type: COMPARATOR
Intervention: Cephalic presentation
Number of subjects: 507
Study 35344210 — intervention group
Group type: EXPERIMENTAL
Intervention: Eryaspase (150 u/kg)
Number of subjects: 55
Study 35344274 — intervention group
Group type: EXPERIMENTAL
Intervention: PillarX device (bimodular microfluidic device)
Number of subjects: 0
Study 35344274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillar-device and X-magnetic device
Number of subjects: 0
Study 35344274 — intervention group
Group type: EXPERIMENTAL
Intervention: PillarX device
Number of subjects: 0
Study 35344570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) assessment of quadriceps rectus femoris and diaphragm muscles using Shear-Wave Elastography (SWE)
Number of subjects: 84
Study 35344570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) assessment of diaphragm and rectus femoris muscles
Number of subjects: 84
Study 35344570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of one diaphragm US marker and one limb muscle US marker
Number of subjects: 84
Study 35344570 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Research Council (MRC) sum score for muscle testing
Number of subjects: 84
Study 35344570 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway occlusion pressure (P0.1)
Number of subjects: 84
Study 35344588 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 0
Study 35344588 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran etexilate (P-gp)
Number of subjects: 0
Study 35344588 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (BCRP and OAT3)
Number of subjects: 0
Study 35344588 — intervention group
Group type: COMPARATOR
Intervention: Metformin (OCT2 and MATE1/2K)
Number of subjects: 0
Study 35344689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry screening for monoclonal gammopathies
Number of subjects: 7622
Study 35344689 — intervention group
Group type: COMPARATOR
Intervention: Serum protein electrophoresis with immunofixation electrophoresis
Number of subjects: 7622
Study 35344689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry screening
Number of subjects: 7622
Study 35344689 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected monoclonal gammopathies
Number of subjects: 7622
Study 35344689 — intervention group
Group type: EXPERIMENTAL
Intervention: All monoclonal gammopathies
Number of subjects: 7622
Study 35345247 — intervention group
Group type: EXPERIMENTAL
Intervention: CONFIRM high-risk model (CHM)
Number of subjects: 5936
Study 35345247 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMISE high-risk model (PHM)
Number of subjects: 5936
Study 35345247 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CHM and PHM
Number of subjects: 5936
Study 35345248 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent P2Y12 inhibitors
Number of subjects: 344
Study 35345248 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 344
Study 35345248 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT (dual antiplatelet therapy)
Number of subjects: 344
Study 35345248 — intervention group
Group type: EXPERIMENTAL
Intervention: History of CVD
Number of subjects: 344
Study 35345248 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI treatment
Number of subjects: 344
Study 35345262 — intervention group
Group type: EXPERIMENTAL
Intervention: New multivariate predictive model for predicting aortic root diameter
Number of subjects: 943
Study 35345262 — intervention group
Group type: COMPARATOR
Intervention: Measured AoR diameter
Number of subjects: 943
Study 35346046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexfin® (non-invasive finger-cuff technology)
Number of subjects: 60
Study 35346046 — intervention group
Group type: EXPERIMENTAL
Intervention: NIBP (oscillometric, non-invasive blood pressure measurement)
Number of subjects: 60
Study 35346046 — intervention group
Group type: COMPARATOR
Intervention: IAP (invasive arterial pressure)
Number of subjects: 60
Study 35346070 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with yttrium-90, target mean dose to tumor is ≥ 150 Gy.
Number of subjects: 100
Study 35346070 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with yttrium-90
Number of subjects: 100
Study 35346138 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative inquiry into lived experiences post-hospitalization for COVID-19
Number of subjects: 150
Study 35346165 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate albuminuria (UACR 30-300 mg/g)
Number of subjects: 9170
Study 35346165 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe albuminuria (UACR > 300 mg/g)
Number of subjects: 9170
Study 35346165 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73 m²
Number of subjects: 9170
Study 35346219 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Medication Therapy (OMT)
Number of subjects: 263
Study 35346244 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-use trails (4-7 km in length) constructed between 2010 and 2012.
Number of subjects: 37901
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in MUO after 3 months
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in MHO after 3 months
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in MUO after 21 months
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in MHO after 21 months
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term HDL-cholesterol improvement in MUO
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term triglycerides improvement in MUO
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) in MUO
Number of subjects: 143
Study 35346256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) in MHO
Number of subjects: 143
Study 35346458 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ pathology at baseline
Number of subjects: 356
Study 35346458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline over time
Number of subjects: 356
Study 35346458 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cognition
Number of subjects: 356
Study 35346720 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen Eyedrops
Number of subjects: 0
Study 35346837 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (aDBS) based on chronic subcortical sensing
Number of subjects: 0
Study 35346837 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic subcortical sensing
Number of subjects: 0
Study 35346837 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable pulse generators (IPG) for recording neural activity
Number of subjects: 0
Study 35346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding back- or front-office staff in past 12 months
Number of subjects: 39
Study 35346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Having staff help patients resolve barriers to CRC screening
Number of subjects: 39
Study 35346927 — intervention group
Group type: EXPERIMENTAL
Intervention: Having staff hand out FITs/educate patients
Number of subjects: 39
Study 35346927 — intervention group
Group type: COMPARATOR
Intervention: Absence of the three support staff factors
Number of subjects: 39
Study 35347368 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal prolapse repair with Elevate anterior and posterior
Number of subjects: 277
Study 35347368 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal prolapse repair with Elevate anterior/apical fixation
Number of subjects: 277
Study 35347368 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal prolapse repair with Elevate posterior/apical fixation
Number of subjects: 277
Study 35347559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily
Number of subjects: 126
Study 35347559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib 700 mg twice daily (micronized V2) with docetaxel 75 mg/m2
Number of subjects: 126
Study 35347559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib (various formulations) plus erlotinib or docetaxel
Number of subjects: 126
Study 35347997 — intervention group
Group type: EXPERIMENTAL
Intervention: Huawei smartwatch monitoring
Number of subjects: 100
Study 35348247 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires and clinical signs of bruxism
Number of subjects: 200
Study 35348247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruxoff® device for recording electromyographic/electrocardiographic data
Number of subjects: 200
Study 35348445 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered exoskeleton
Number of subjects: 0
Study 35348445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35348754 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg orally daily)
Number of subjects: 15
Study 35349025 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Partner Guide (PPG) - a five-step workbook providing practical tools and resources for clinic QI teams.
Number of subjects: 20
Study 35349025 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of patient co-investigators in research.
Number of subjects: 20
Study 35349025 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the PPG in clinics undertaking the QI project.
Number of subjects: 20
Study 35349076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 33
Study 35349076 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 33
Study 35349129 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of dexamethasone
Number of subjects: 0
Study 35349129 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of dexamethasone
Number of subjects: 0
Study 35349162 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cefazolin)
Number of subjects: 390
Study 35349186 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 1142
Study 35349186 — intervention group
Group type: COMPARATOR
Intervention: Control groups (usual rehabilitation or occupational therapy care)
Number of subjects: 1142
Study 35349186 — intervention group
Group type: COMPARATOR
Intervention: Control groups (waiting list)
Number of subjects: 1142
Study 35349331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg/m) added to conventional AML chemotherapy
Number of subjects: 72
Study 35349331 — intervention group
Group type: COMPARATOR
Intervention: Conventional AML chemotherapy
Number of subjects: 72
Study 35349380 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35349466 — intervention group
Group type: EXPERIMENTAL
Intervention: PositiveLinks (PL) mHealth intervention
Number of subjects: 482
Study 35349466 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 482
Study 35349491 — intervention group
Group type: EXPERIMENTAL
Intervention: CIML NK cells infused after lymphodepleting chemotherapy (5 to 10 million cells/kg) followed by systemic IL-2 for 7 doses.
Number of subjects: 6
Study 35349491 — intervention group
Group type: EXPERIMENTAL
Intervention: CIML NK cells
Number of subjects: 6
Study 35349631 — intervention group
Group type: EXPERIMENTAL
Intervention: huCART-19
Number of subjects: 20
Study 35349683 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil supplement (2 g/d for 28-30 days)
Number of subjects: 23
Study 35350054 — intervention group
Group type: EXPERIMENTAL
Intervention: Asians (N = 317)
Number of subjects: 1253
Study 35350054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks (N = 158)
Number of subjects: 1253
Study 35350054 — intervention group
Group type: EXPERIMENTAL
Intervention: Whites (N = 736)
Number of subjects: 1253
Study 35350054 — intervention group
Group type: EXPERIMENTAL
Intervention: Other races (N = 42)
Number of subjects: 1253
Study 35350054 — intervention group
Group type: COMPARATOR
Intervention: Asians compared to Blacks
Number of subjects: 1253
Study 35350054 — intervention group
Group type: COMPARATOR
Intervention: Asians compared to Whites
Number of subjects: 1253
Study 35350054 — intervention group
Group type: COMPARATOR
Intervention: Whites compared to Blacks
Number of subjects: 1253
Study 35350411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education
Number of subjects: 221
Study 35350411 — intervention group
Group type: COMPARATOR
Intervention: Control (no nutritional education)
Number of subjects: 221
Study 35350582 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted reaching and hand-to-mouth movements, 12 sessions of 40 minutes each, 3 times per week
Number of subjects: 19
Study 35350582 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted reaching and hand-to-mouth movements
Number of subjects: 19
Study 35350834 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of the COVID-19 vaccine
Number of subjects: 100
Study 35350834 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of the COVID-19 vaccine
Number of subjects: 100
Study 35350834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of the COVID-19 vaccine
Number of subjects: 100
Study 35350938 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT) targeting CD33, CD45, or CD66
Number of subjects: 0
Study 35350948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study 35351093 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care intervention (CCI)
Number of subjects: 242
Study 35351093 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 242
Study 35351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers (female)
Number of subjects: 218
Study 35351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers (male)
Number of subjects: 218
Study 35351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive depression screening
Number of subjects: 218
Study 35351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived burden (female caregivers)
Number of subjects: 218
Study 35351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic help (male caregivers)
Number of subjects: 218
Study 35351106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Science Education (PSE)
Number of subjects: 15
Study 35351181 — intervention group
Group type: EXPERIMENTAL
Intervention: p-tau217 alone
Number of subjects: 110
Study 35351181 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of p-tau217 with hippocampal volume, cognition, and APOE genotype
Number of subjects: 110
Study 35351181 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of p-tau217 and cognition
Number of subjects: 110
Study 35351214 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive intravenous fluid protocol
Number of subjects: 124
Study 35351214 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study 35351714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health-based programme for HIV and TB integration
Number of subjects: 60
Study 35351731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diagnostic accuracy study
Number of subjects: 0
Study 35351823 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) for rheumatic AS
Number of subjects: 105
Study 35351823 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) for degenerative AS
Number of subjects: 105
Study 35352025 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35352097 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dose monitoring (EDM) for ART adherence
Number of subjects: 198
Study 35352097 — intervention group
Group type: EXPERIMENTAL
Intervention: ART adherence
Number of subjects: 198
Study 35352097 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ART adherence
Number of subjects: 198
Study 35352102 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily coformulated tenofovir disoproxil fumarate and emtricitabine for HIV prevention
Number of subjects: 9596
Study 35352313 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 or 8 weeks
Number of subjects: 739
Study 35352313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 35352512 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg IV every 2 weeks for three cycles) plus hypofractionated radiotherapy (5 Gy × 5)
Number of subjects: 0
Study 35352564 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Observation Group Criteria of the ESC 0/1-Hour Algorithm
Number of subjects: 0
Study 35352604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Number of subjects: 233
Study 35352766 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium bromide delivered via pressurized metered-dose inhaler with holding chamber and systemic corticosteroids
Number of subjects: 60
Study 35352882 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-anticoagulated atrial fibrillation patients
Number of subjects: 9503
Study 35352882 — intervention group
Group type: COMPARATOR
Intervention: OAC-naïve AF cohort
Number of subjects: 9503
Study 35353154 — intervention group
Group type: COMPARATOR
Intervention: Dual pathway inhibition (DPI) with a P2Y12 inhibitor (clopidogrel or ticagrelor) and a vascular dose of rivaroxaban
Number of subjects: 40
Study 35353154 — intervention group
Group type: COMPARATOR
Intervention: DAPT with a P2Y12 inhibitor (clopidogrel or ticagrelor)
Number of subjects: 40
Study 35353154 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based DPI
Number of subjects: 40
Study 35353197 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring system based on four independent variables (hemodynamic instability, involvement of the small bowel, paper-thin wall pattern, no stratified enhancement pattern)
Number of subjects: 205
Study 35353197 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring system validated in external cohort
Number of subjects: 205
Study 35353197 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring system categorized patients into low risk (score: 0, 1), high risk (score: 2-3), and very high risk (score: 4-7)
Number of subjects: 205
Study 35353219 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH305 at doses 75-750 mg twice daily
Number of subjects: 41
Study 35353219 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH305
Number of subjects: 41
Study 35353229 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of family meals
Number of subjects: 1964